Results 181 to 190 of about 29,969,840 (342)

In Situ Growth of Metallic 1T-MoS2 on TiO2 Nanotubes with Improved Photocatalytic Performance

ACS Omega, 2021
Miaogen Chen, Tao Sun, Wan Zhao, Xiuru Yang, Wenya Chang, Xiaoxiao Qian, Qian Yang, Zhi Chen   +7 more
doaj   +1 more source

Water resources data for Oregon, water year 1974; Part 2, Water quality records [PDF]

, 1975
Min Min, Max Min, Min Min, Sium Bonate Bonate, Sulfate Ride   +4 more
openalex   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Establishing Best Practices for Clinical GWAS: Tackling Imputation and Data Quality Challenges. [PDF]

Int J Mol Sci
Casaburi G, McCullough R, D'Argenio V.
europepmc   +1 more source

Water resources data for California, 1974; Part 2: Water quality records [PDF]

, 1975

openalex   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Regulatory landscape with U.S. patient requirements and Clinical Trial Diversity expectations

Contemporary Clinical Trials Communications
The Food and Drug Administration (FDA) has an expectation that products filed for marketing authorization have to include data that are representative of the US patient population.
Elizabeth George, Alicia Baker McDowell, Melissa Vozza, Talley Mitchell, Ben Quartley, Cassandra S. Kennedy, Bill Hanlon   +6 more
doaj  

Accounting for population structure and data quality in demographic inference with linkage disequilibrium methods. [PDF]

Nat Commun
Santiago E, Köpke C, Caballero A.
europepmc   +1 more source

Water resources data for Pennsylvania, water year 1973; Part 2, Water quality records [PDF]

, 1974
U.S. Geological Survey
openalex   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source